IP Group (LON:IPO) Releases Quarterly Earnings Results

IP Group (LON:IPO) announced its earnings results on Tuesday. The company reported GBX 7.24 earnings per share (EPS) for the quarter, Digital Look Earnings reports. IP Group had a negative return on equity of 15.13% and a net margin of 117.22%.

Here are the key takeaways from IP Group’s conference call:

• Reported full‑year NAV per share rose to £1.10 (up 13% YoY) driven by realizations and valuation gains, demonstrating tangible portfolio value growth.
• Recognised a fair value of £128m for long‑dated royalty/milestone rights from the Pfizer/Metsera obesity programs, providing meaningful upside while noting remaining clinical, regulatory and commercial risks.
• Returned capital via a £45m buyback in 2025 (retiring ~10% of shares at large discounts) and earmarked ~£30m for future buybacks, confirming buybacks are a primary tool when shares trade well below NAV.
• Portfolio momentum: companies raised >£900m of third‑party capital (up ~17% YoY) and several assets delivered strong exits or fundraising (e.g., Hinge Health, Monolith, Artios), increasing routes to future cash realizations.
• Despite progress, the market continues to value IP Group at a substantial discount to NAV (well over 50% at the time of the call), leaving the share price disconnected from reported intrinsic value and posing ongoing downside/market perception risk.

IP Group Stock Performance

Shares of IPO stock opened at GBX 52.99 on Tuesday. The company has a debt-to-equity ratio of 16.10, a quick ratio of 8.59 and a current ratio of 15.42. The firm has a market cap of £468.14 million, a price-to-earnings ratio of -3.71 and a beta of 1.29. IP Group has a 52 week low of GBX 34.35 and a 52 week high of GBX 66.16. The firm’s 50-day simple moving average is GBX 56.42 and its two-hundred day simple moving average is GBX 57.52.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank restated a “buy” rating and set a GBX 100 price objective on shares of IP Group in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of GBX 100.

About IP Group

IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK’s largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach.